Adrian Messerli, MD
Interventional Cardiology · Lexington, KYNPI 1659383289
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $30,683 of the $40,833 with a category attached, or 75.1%. EKOS Corporation accounts for 75.3% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2019 at $30,904 and has fallen 99.4% since, to $180 in 2024.
Across 49 payments — averaging $833.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- EKOS Corporation$31K
- Boston Scientific$9K
- Biotronik Inc.$299
- Shockwave Medical, Inc$180
- Abiomed$150
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$136
- plus $117 from 5 others
Across 7 payments — averaging $2856.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- EKOS Corporation$16K
- Boston Scientific$4K
What the payments were for
- Consulting fees$9002%
- Speaking & faculty fees$30,68375%
- Travel & lodging$6,61316%
- Food & beverage$2,6376%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| EKOS Corporation | 26 | $30,765 |
| Boston Scientific | 11 | $9,186 |
| Biotronik Inc. | 3 | $299 |
| Shockwave Medical, Inc | 1 | $180 |
| Abiomed | 1 | $150 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $136 |
| Cardiovascular Systems Inc. | 1 | $46 |
| Akcea Therapeutics, Inc. | 1 | $27 |
| Amgen | 1 | $16 |
| AstraZeneca | 1 | $15 |
| Lundbeck LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$40,833 in reported general payments places this provider in the 80th percentile of 129 interventional cardiology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 39 | $45,602 |
| Repatha SureclickEvolocumab | 21 | $18,378 |
| XareltoRivaroxaban | 15 | $15,623 |
| Atorvastatin Calcium | 83 | $563 |
| Metoprolol Succinate | 51 | $554 |
| ClopidogrelClopidogrel Bisulfate | 63 | $546 |
| Valsartan | 19 | $484 |
| Carvedilol | 55 | $319 |
| Amlodipine Besylate | 85 | $317 |
| Rosuvastatin Calcium | 19 | $297 |
| Lisinopril | 38 | $241 |
| Nitroglycerin | 25 | $224 |
| Ezetimibe | 13 | $194 |
| Pantoprazole Sodium | 23 | $174 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 19 | $170 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Lexington
- Avichai EresLexington$616K
- Steve LinLexington$362K
- Robert SawyerLexington$249K
- Ganesh Keshav ThirunavukkarasuLexington$220K
- Armaghan SoomroLexington$117K
- Hussam HamdallaLexington$24K
- Henry Charles RichmondLexington$20K
- Michael ShihLexington$20K
- Mubashir QaziLexington$18K
- Michael RukavinaLexington$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.